159634-94-3Relevant articles and documents
A practical synthesis of the pseudotripeptide RC-1291
Paul, Bernhard J.,Littler, Benjamin J.,Jos, Frederic,Vogt, Paul F.,Pines, Seemon H.
, p. 339 - 345 (2012/12/22)
The rapid process development of a scaleable synthesis of the pseudotripeptide RC-1291 for preclinical and clinical evaluation is described. By employing a nontraditional N-to-C coupling strategy, the peptide chain of RC-1291 was assembled in high yield, with minimal racemization and in an economical manner by introducing the most expensive component last. A one-pot deprotection/crystallization procedure was developed for the isolation of RC-1291 free base, which afforded the target compound in excellent yield and with a purity of >99.5% without chromatographic purification.
Heterocyclic compounds
-
, (2008/06/13)
This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920. The invention is also directed to intermediates useful in the preparation of compounds of formula I.
Tripeptide growth hormone secretagogues
Yang, Lihu,Morriello, Greg,Pan, Yanping,Nargund, Ravi P.,Barakat, Khaled,Prendergast, Kristine,Cheng, Kang,Chan, Wanda W.-S.,Smith, Roy G.,Patchett, Arthur A.
, p. 759 - 764 (2007/10/03)
A series of C-terminus capped dipeptides and tripeptides was synthesized as growth hormone (GH) sccretagogues. Among them, tripeptide Aib-D-Trp-D-homoPhe-OEt showed low nanomolar activity in the rat pituitary assay. Thus, we have demonstrated that the GH secretagogue activity of the hexa- hepta-GH releasing peptides can be mimicked at the tripeptide level.